The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131.
 
Michael Burke
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - Jazz Pharmaceuticals
Speakers' Bureau - Jazz Pharmaceuticals
 
Meenakshi Devidas
No Relationships to Disclose
 
Si Chen
No Relationships to Disclose
 
Lia Gore
Employment - ARIAD (I)
Leadership - ARIAD (I)
Stock and Other Ownership Interests - Amgen; ARIAD; ARIAD (I); Celgene; Sanofi
Honoraria - Genentech/Roche; Jazz Pharmaceuticals; Seagen
Consulting or Advisory Role - Meryx Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent held for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia.
Travel, Accommodations, Expenses - Amgen
 
Eric Larsen
No Relationships to Disclose
 
Joanne M. Hilden
No Relationships to Disclose
 
Mignon L. Loh
No Relationships to Disclose
 
Naomi J. Winick
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - Jazz Pharmaceuticals
 
William L. Carroll
No Relationships to Disclose
 
Elizabeth A. Raetz
No Relationships to Disclose
 
Stephen Hunger
Stock and Other Ownership Interests - Amgen; Amgen (I); Express Scripts; Merck (I); Pfizer (I)
Honoraria - Jazz Pharmaceuticals; Sigma-Tau
Patents, Royalties, Other Intellectual Property - I am a co-Inventor on a US patent #8,568,974 B2 Identification of novel subgroups of high-risk pediatric precursor-B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same. It has not be licensed and the
Travel, Accommodations, Expenses - Amgen
 
Wanda L. Salzer
No Relationships to Disclose